Arcturus Therapeutics

ARCT

Market cap $589M

Arcturus Therapeutics (ARCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arcturus Therapeutics Holdings Inc. (ARCT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ARCT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences: Citi's 2025 Biopharma Back to School Conference (Fireside Chat) Tuesday, September 2, 2025 (11:15 a.m. ET) 2025 Wells Fargo Healthcare Conference (.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2025 Earnings Conference August 11, 2025 4:30 PM ET Company Participants Andrew H. Sassine - CFO & Director Joseph E.

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $0.64 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates. “The Company continues to advance and provide meaningful clinical data across our mRNA therapeutics and vaccines pipeline,.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: BTIG Virtual Biotechnology Conference 2025 (Fireside Chat) Tuesday, July 29, 2025 (12:40 p.m. ET) CG 45th Annual Growth Conference (Presen.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announces positive Phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia cr.